Skip to Content
Merck
  • Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.

Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics.

Anticancer research (2020-09-04)
Minori Kamada, Keiichi Ikeda, Yoshinobu Manome
ABSTRACT

Nicotinamide phosphoribosyl-transferase (NAMPT) is a rate-limiting enzyme in the pathway synthesizing nicotinamide adenine dinucleotide (NAD (+)) from nicotinamide (NAM). Glioma tissues exhibit up-regulated NAMPT expression associated with a poor prognosis of patients. To determine if NAMPT can be a molecular therapeutic target, we investigated the effects of short hairpin RNA (shRNA)-mediated NAMPT down-regulation. We designed shRNA to NAMPT and transfected to T98G cells. The characteristics of these cells were analyzed. The NAMPT shRNA-transfected cells exhibited delayed cell growth. However, there was no difference in the increase of sensitivity to temozolomide (TMZ) or X-ray irradiation between the NAMPT and scramble shRNA-transfected cells. The expression of NAMPT in the NAMPT shRNA-transfected cells increased with cell passage. Additionally, the shRNA-mediated transfection was associated with enhanced expression of quinolinic acid phosphoribo-syltransferase (QPRT). shRNA-mediated NAMPT down-regulation may not decrease the NADt to a sufficient level to increase TMZ/radiation sensitivity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-QPRT antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-74, ascites fluid
Sigma-Aldrich
Monoclonal Anti-NAPRT antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL0665, purified immunoglobulin, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-MGMT Antibody, clone MT3.1, clone MT3.1, Chemicon®, from mouse